Bregt S Kappelhoff
Overview
Explore the profile of Bregt S Kappelhoff including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
193
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Postma M, Kappelhoff B, van Hulst M, Brouwers J
J Med Econ
. 2013 Mar;
16(3):372-3.
PMID: 23530272
No abstract available.
2.
Postma M, Kappelhoff B, van Hulst M, Brouwers J
J Med Econ
. 2012 May;
15(5):878-86.
PMID: 22563715
Objectives: Dabigatran etexilate is a new oral direct thrombin inhibitor for prophylaxis of venous thromboembolism (VTE) in patients who have elective surgery for total hip replacement (THR) or total knee...
3.
Hubben G, Bos J, Veltman-Starkenburg C, Stegmeijer S, Finnern H, Kappelhoff B, et al.
Cost Eff Resour Alloc
. 2007 Nov;
5:15.
PMID: 18034881
Background: This study compares the costs and effects of a regimen with ritonavir-boosted tipranavir (TPV/r) to a physician-selected genotypically-defined standard-of-care comparator protease inhibitor regimen boosted with ritonavir (CPI/r) in HIV...
4.
Kappelhoff B, Huitema A, van Leth F, Robinson P, MacGregor T, Lange J, et al.
HIV Clin Trials
. 2005 Nov;
6(5):254-61.
PMID: 16306032
Objective: As part of the large international, randomized 2NN trial, the pharmacokinetics of nevirapine in once-daily 400 mg and twice-daily 200 mg dosing regimens were investigated. Method: Treatment-naive HIV-1-infected patients...
5.
Kappelhoff B, Huitema A, Sankatsing S, Meenhorst P, van Gorp E, Mulder J, et al.
Br J Clin Pharmacol
. 2005 Aug;
60(3):276-86.
PMID: 16120066
Aims: The aim of the study was to characterize the population pharmacokinetics of indinavir, define the relationship between the pharmacokinetics of indinavir and ritonavir, and to identify the factors influencing...
6.
Kappelhoff B, van Leth F, Robinson P, MacGregor T, Baraldi E, Montella F, et al.
Antivir Ther
. 2005 Jul;
10(4):489-98.
PMID: 16038474
Objective: The relationships between adverse events (AEs) and plasma concentrations of nevirapine (NVP) and efavirenz (EFV) were investigated as part of the large, international, randomized 2NN study. Methods: Treatment-naive, HIV-1-infected...
7.
Kappelhoff B, Huitema A, Yalvac Z, Prins J, Mulder J, Meenhorst P, et al.
Clin Pharmacokinet
. 2005 Jul;
44(8):849-61.
PMID: 16029069
Objective: The aim of this study was to characterise the population pharmacokinetics of efavirenz in a representative patient population and to identify patient characteristics influencing the pharmacokinetics of efavirenz, with...
8.
Kappelhoff B, Huitema A, Mairuhu A, Schellens J, Beijnen J
Anticancer Drugs
. 2005 Jun;
16(6):627-30.
PMID: 15930890
We have investigated the pharmacokinetics of nevirapine and paclitaxel in a patient who used both drugs concomitantly, as there are strong theoretical indications for a potential pharmacokinetic drug-drug interaction. Plasma...
9.
Kappelhoff B, Huitema A, Beijnen J
Drugs R D
. 2005 Mar;
6(2):61-9.
PMID: 15777100
In the treatment of HIV-infected patients, an urgent need exists for more conveniently dosed and better tolerated regimens with improved virological and immunological efficacy. Based on preclinical studies, the combination...
10.
Kappelhoff B, van Leth F, MacGregor T, Lange J, Beijnen J, Huitema A
Antivir Ther
. 2005 Mar;
10(1):145-55.
PMID: 15751772
Objective: The aim of this 2NN pharmacokinetic substudy was to investigate the population pharmacokinetics of nevirapine and efavirenz. Methods: Treatment-naive, HIV-1-infected patients received nevirapine (once or twice daily), efavirenz or...